HCYT Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (7 Jul 2023 @ 15:00):

H-CYTE, Inc., a biopharmaceutical company, develops and delivers various treatments for patients with chronic respiratory and pulmonary disorders in the United States...

Stats
Today's Volume	325.00
Average Volume	796.00
Market Cap	624 980
EPS	$0 ( 2024-05-20 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0642
ATR14	$0.236 (23.60%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-16	Wagner Todd R	Sell	303 107 000	SERIES A PREFERRED STOCK
2024-01-16	Wagner Todd R	Buy	303 107	COMMON STOCK
2024-01-16	Farrior J Rex Iii	Sell	13 168 000	SERIES A PREFERRED STOCK
2024-01-16	Farrior J Rex Iii	Buy	13 168	COMMON STOCK
2022-03-21	Lynch Frederick J	Sell	8 321 785	STOCK PURCHASE WARRANTS

INSIDER POWER
-99.80
Last 90 transactions
Buy: 833 204 294 \| Sell: 379 884 747

Volume Correlation

Long: -0.31 (neutral)

Short: 0.58 (weak)

Signal:(32.745) Neutral

H-CYTE, Inc. Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

H-CYTE, Inc. Correlation - Currency/Commodity

-0.38
( neutral )

0.10
( neutral )

-0.17
( neutral )

0.19
( neutral )

H-CYTE, Inc. Financials

Annual	2022
Revenue:	$453 460
Gross Profit:	$335 859 (74.07 %)
EPS:	$-49.51

FY	2022
Revenue:	$453 460
Gross Profit:	$335 859 (74.07 %)
EPS:	$-49.51

FY	2021
Revenue:	$1.61M
Gross Profit:	$906 813 (56.27 %)
EPS:	$-30.00

FY	2020
Revenue:	$2.15M
Gross Profit:	$1.38M (64.34 %)
EPS:	$-60.00

Financial Reports:

No articles found.

H-CYTE, Inc. Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

H-CYTE, Inc.

H-CYTE, Inc., a biopharmaceutical company, develops and delivers various treatments for patients with chronic respiratory and pulmonary disorders in the United States. The company develops and implements treatment options in autologous cellular therapy to treat chronic lung disorders. It has a product supply agreement with Rion, LLC to develop and distribute a biologic for chronic obstructive pulmonary disease. The company is headquartered in Tampa, Florida.